## AMENDMENT

Please amend the claims as follows:

J,

Please cancel claims 31, 41 and 47, without prejudice.

- 32. The expression vector of claim [31] <u>52</u> wherein said fusion immunoglobulin comprises a heavy chain and [has said] at least one [tolerogenic] epitope [inserted] <u>positioned</u> adjacent to the first framework region of the N-terminus variable region of [the] <u>said</u> heavy chain.
  - 33. The vector of claim [31] 52 which is a retroviral vector.
- 34. The vector of claim [31] <u>52</u> wherein said antigen <u>mediates</u> [is associated with] an allergic reaction [and is] <u>to</u> an antigen <u>selected from the group consisting of:</u> pollen <u>antigen</u>, ragweed antigen, [or] and dust mite <u>antigen</u>.
- 35. The expression vector of claim [31] <u>52</u> wherein said antigen is an autoantigen <u>of</u> an expression host cell and is selected from the group consisting of: clotting factor VIII, acetylcholine receptors, collagen, myelin basic protein, thyroglobulin, and histocompatibility antigen.
- 36. The expression vector of claim [31] <u>52</u> which contains more than one copy of the nucleotide sequence encoding said epitope.
- 37. The expression vector of claim [31] <u>52</u> wherein the fusion immunoglobulin is an IgG.
- 38. The expression vector of claim [31] <u>52</u> which [has] <u>comprises</u> the <u>identifying</u> characteristics of ATCC No. 69555.

- 39. A transformed haemopoietic or lymphoid cell comprising the expression vector of claim [31] 52.
- 42. The expression vector of claim [41] <u>53</u> wherein said antigen <u>mediates</u> [is associated with] autoimmune disease or allergic reactions [of] in said [animal] mammal.
- 44. The expression vector of claim 42 wherein said antigen is an autoantigen and is selected from the group consisting of: clotting factor VIII, acetylcholine receptors, collagen, myelin basic protein, thyroglobulin, and histocompatibility antigen.
- 45. The expression vector of claim [41] <u>53</u> which contains more than one copy of the nucleotide sequence encoding said epitope.
- 46. A transformed haemopoietic or lymphoid cell comprising the expression vector of claim [41] <u>53</u>.
- 48. The expression vector of claim [47] <u>54</u> wherein said antigen is associated with autoimmune disease or allergic reactions of said [animal] mammal.
- 50. The expression vector of claim 48 wherein said antigen is an autoantigen and is selected from the group consisting of: clotting factor VIII antigen, acetylcholine receptors antigen, collagen antigen, myelin basic protein antigen, thyroglobulin antigen, and histocompatibility antigen.
  - 51. A transformed haemopoietic or lymphoid cell comprising the expression vector of claim [41] 53.

Please add the following new claims:

--52. (New) An expression vector comprising:

a nucleotide sequence encoding a fusion immunoglobulin heavy or light chain operably linked to a promoter sequence operational for expression of said nucleotide sequence in a haemopoietic or lymphoid cell in a mammalian host;

wherein said fusion immunoglobulin comprises: an N-terminal variable region of said heavy or light chain; and wherein said N-terminal variable region further comprises at least one amino acid sequence that encodes an antigen epitope heterologous to said host cell; and

wherein the expression of said vector in said haemopoietic or lymphoid cell of said fusion immunoglobulin induces immunological tolerance to said antigen epitope in said mammalian host.

## 53. (New) An expression vector comprising:

a nucleotide sequence encoding a fusion immunoglobulin heavy or light chain operably linked to a promoter sequence operational for expression of said nucleotide sequence in a haemopoietic or lymphoid cell in a mammalian host;

wherein said fusion immunoglobulin comprises: an N-terminal variable region of said heavy or light chain; and wherein said N-terminal variable region further comprises at least one amino acid sequence that encodes an antigen epitope heterologous to said host cell; and

wherein the expression of said vector in said haemopoietic or lymphoid cell of said fusion immunoglobulin induces immunological tolerance to said antigen epitope in said mammalian host; and wherein said vector is a retroviral vector.

## 54. (New) An expression vector comprising:

a nucleotide sequence encoding a fusion immunoglobulin heavy or light chain operably linked to a promoter sequence operational for expression of said nucleotide sequence in a haemopoietic or lymphoid cell in a mammalian host;

wherein said fusion immunoglobulin comprises: an N-terminal variable region of said heavy or light chain; and wherein said N-terminal variable region further comprises at least one amino acid sequence that encodes an antigen epitope heterologous to said host cell; and

wherein the expression of said vector in said haemopoietic or lymphoid cell of said fusion immunoglobulin induces immunological tolerance to said antigen epitope in said mammalian host; and wherein said vector is a retroviral vector; and